Table 1 Genetic alteration signatures of m6A modification genes in samples of lung squamous cell cancer from TCGA (n = 178)
| Â | Genetic alteration | |||||||
|---|---|---|---|---|---|---|---|---|
| Â | Â | Â | Mutation | CNV | ||||
| Â | Â | No alterations | Missense mutation | Splice | Truncating mutation | Amplification | Deep deletion | Altered/profiled |
Writer | METTL3 | 173 | 1 | 0 | 0 | 1 | 3 | 2.81% |
METTL14 | 177 | 1 | 0 | 0 | 0 | 0 | 0.56% | |
METTL16 | 173 | 3 | 0 | 0 | 0 | 2 | 2.81% | |
WTAP | 175 | 1 | 1 | 0 | 0 | 1 | 1.69% | |
RBM15 | 174 | 0 | 0 | 1 | 0 | 3 | 2.25% | |
RBM15B | 176 | 1 | 0 | 0 | 0 | 1 | 1.12% | |
CBLL1 | 171 | 4 | 0 | 0 | 3 | 0 | 3.93% | |
VIRMA | 169 | 3 | 1 | 1 | 4 | 0 | 5.06% | |
ZC3H13 | 171 | 4 | 0 | 0 | 0 | 3 | 3.93% | |
Eraser | FTO | 173 | 3 | 0 | 0 | 0 | 2 | 2.81% |
ALKBH5 | 175 | 0 | 0 | 0 | 1 | 2 | 1.69% | |
Reader | YTHDC1 | 170 | 2 | 0 | 0 | 6 | 0 | 4.49% |
YTHDC2 | 174 | 4 | 0 | 0 | 0 | 0 | 2.25% | |
YTHDF1 | 175 | 1 | 0 | 0 | 2 | 0 | 1.69% | |
YTHDF2 | 177 | 1 | 0 | 0 | 0 | 0 | 0.56% | |
YTHDF3 | 169 | 3 | 0 | 0 | 6 | 0 | 5.06% | |
IGF2BP1 | 173 | 2 | 0 | 1 | 2 | 0 | 2.81% | |
IGF2BP2 | 88 | 3 | 0 | 0 | 87 | 0 | 50.56% | |
IGF2BP3 | 172 | 0 | 0 | 0 | 6 | 0 | 3.37% | |